[Germ cell cancer--an update].
Recently a rise in the incidence of testicular germ cell cancer (TGCC) has been repeatedly reported in Germany (18% during the period 2000-2006). Future investigations are needed to examine causes for this increase in TGCT. The mortality rates in the western and eastern parts of Germany converge, but there is still a significantly higher mortality rate in the eastern part. Again future investigations are needed to examine causes for this phenomenon. In cases of testicular microlithiasis, testicular biopsies should be considered if further factors representing testicular dysgenesis syndrome are present, such as infertility, atrophic testes, and undescended testes. One course of adjuvant BEP reduces the risk of relapse by approximately 90% and may be a new option as the initial treatment for all CS1 NSGCT. Patients obtaining a CR (<1 cm) after first-line chemotherapy can be safely observed without PC-RPLND. Relapses are rare and potentially curable with further treatment.
Schrader
M
M
Klinik für Urologie, Universitätsklinikum Ulm, Prittwitzstrasse 43, 89075, Ulm. mark.schrader@uniklinik-ulm.de
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal; D015995:Prevalence; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents
J Clin Oncol. 2009 May 1;27(13):2122-8
19307506
Ann Oncol. 2008 Mar;19(3):443-7
18048383
J Clin Oncol. 2009 Sep 10;27(26):4327-32
19652075
Lancet. 2005 Jul 23-29;366(9482):293-300
16039331
J Urol. 2008 Apr;179(4):1420-3; discussion 1423
18289592
J Cancer Res Clin Oncol. 2010 Feb;136(2):227-32
19680688
J Clin Oncol. 2010 Feb 1;28(4):531-6
20026808
Urology. 2004 Mar;63(3):556-61
15028457